Featured Research

from universities, journals, and other organizations

Sweet test to reduce false-positive cancer diagnoses

Date:
March 10, 2014
Source:
University of Copenhagen - Faculty of Science
Summary:
New sugar-test appears to reduce false-positive cancer diagnoses for ovarian cancer. Currently, the world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. The newly test, under development, uses a method able to halve this number. When fully developed, the new test will spare a significant number of women from unnecessary worry and further testing. Furthermore, global health care providers stand to save substantial sums -- just by including a test on a certain sugar molecule in tandem with the currently prevailing diagnostic test.

Professor Ola Blixt testing for sugars in his Copenhagen lab.
Credit: Image courtesy of University of Copenhagen - Faculty of Science

The world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. Now, chemists at the University of Copenhagen working with clinical researchers at University College London have developed a method able to halve the number of false-positives. When fully developed, the new test will spare a significant number of women from unnecessary worry and further testing. Furthermore, global health care providers stand to save substantial sums -- just by including a test on a certain sugar molecule in tandem with the currently prevailing diagnostic test.

Ola Blixt is a chemical glycobiology professor at the Department of Chemistry, University of Copenhagen. He and Professor Usha Menon have led the research efforts of the teams at the Gynaecological Cancer Research Centre, University College London and the Copenhagen Center for Glycomics, who have succeeded in developing this new method that tests for ovarian cancer. The method helps distinguish between cancer and otherwise benign conditions and is called glycoprofiling. It has been published in the Journal of Proteome Research, under the title "Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer."

Vital to clear misdiagnosed women

Ola Blixt hopes that glycoprofiling will be incorporated in prevailing ovarian cancer diagnostics "kits" because there is simply so much distress that follows in the wake of a false diagnosis. "When a woman is informed that she might have cancer, she will always be terrified. She will also require further testing and this can be uncomfortable. Furthermore, there is the risk that she will encounter a considerable wait time before being provided with an accurate answer. I think that it is vital to clear those women who are misdiagnosed with cancer in a quick and safe manner. Our researches suggests that the new method, glycoprofiling, could improve differential diagnosis and significantly reduce the number of patients elected for further testing," says Blixt.

Test targets markers elevated by benign conditions too

Three-percent of all women will be tested for ovarian cancer in their lifetimes. In the United States alone, every year 100,000 women receive the distressing message that they might have cancer, following the initial test.

Women with ovarian cancer have an elevated amount of a protein known as CA125 in their blood. Therefore, current tests focus on this protein. Unfortunately, a wide range of other and far more benign conditions also increases CA125 figures. These include benign cysts, infections and even menstruation and pregnancy.

Sugar transformed by cancer

Ola Blixt directs the new diagnostic tests at an entirely different biological molecule, namely a sugar that coats the surface of the CA125 protein. Blixt explains that the presence of this specific sugar is limited to women who really are affected by ovarian cancer.

"All proteins have a type of sugar-coat -- small, complicated sugar molecules that reside on a protein's surface. When cancer is present in the body, we can observe a chemical change in this sugar-coat. It is a very complex phenomenon. Luckily, it is very simple to investigate and determine the presence of this transformed sugar coating," states Blixt.

Unpatented discovery allows for immediate integration

In principle, the sugar testers could be included in the currently prevalent diagnostic kits immediately. In the lab, Blixt and his PhD student, Kowa Chen, tested a plant lectin and and a monoclonal antibody. Both serve to reveal the specific sugar, and both are cheap and easy to get a hold of. The way is even cleared for willing manufacturers, explains Blixt.

"We have decided to publish these results, as opposed to taking out a patent. OK, we won't get rich, even though the market related to ovarian cancer is worth 170 million dollars annually. On the other hand, any manufacturer is able to include this in their existing kit. And I hope that it happens soon," says Blixt.

Paying a debt to ailing contributors

In the glycoprofiling project, Blixt and Chen worked with Professor Usha Menon and Dr Gentry Maharaj to analyse samples gathered in the UK Ovarian Cancer Population Study (UKOPS). Blixt feels indebted to the women who contributed their blood samples to the research.

"Each of these samples has a sad story behind it. Our results can't help those women who provided us with the tests, but we owe it to the women to try to get our method out as far and wide as possible, so that their sacrifice has not been in vain," says Blixt.

In time, Blixt expects the glycoprofiling method to improve diagnoses for a range of other cancer types.

"But I'm just a university researcher. We have demonstrated a method that works. Now companies must pick up the ball and refine it," concludes Professor Blixt.


Story Source:

The above story is based on materials provided by University of Copenhagen - Faculty of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kowa Chen, Aleksandra Gentry-Maharaj, Matthew Burnell, Catharina Steentoft, Lara Marcos-Silva, Ulla Mandel, Ian Jacobs, Anne Dawnay, Usha Menon, Ola Blixt. Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer. Journal of Proteome Research, 2013; 12 (3): 1408 DOI: 10.1021/pr3010474

Cite This Page:

University of Copenhagen - Faculty of Science. "Sweet test to reduce false-positive cancer diagnoses." ScienceDaily. ScienceDaily, 10 March 2014. <www.sciencedaily.com/releases/2014/03/140310090745.htm>.
University of Copenhagen - Faculty of Science. (2014, March 10). Sweet test to reduce false-positive cancer diagnoses. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2014/03/140310090745.htm
University of Copenhagen - Faculty of Science. "Sweet test to reduce false-positive cancer diagnoses." ScienceDaily. www.sciencedaily.com/releases/2014/03/140310090745.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins